model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Gemini-3-Pro,protocolSection.identificationModule.nctId,TP,TP,NCT02341625,NCT02341625,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.briefTitle,TP,TP,A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,Safety and Tolerability of BMS-986148 ± Nivolumab in Patients with Selected Tumors,True,0.86,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.identificationModule.officialTitle,TP,TP,"A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors","A Global, Phase I/IIa Trial Assessing Safety, Tolerability, and Preliminary Efficacy of BMS-986148 ± Nivolumab in Patients with Mesothelin-Expressing Tumors",True,0.74,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.briefSummary,TP,TP,"The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.","This phase I/IIa study assesses the safety, tolerability, and preliminary efficacy of BMS-986148, a mesothelin-directed antibody–drug conjugate (ADC), administered as a monotherapy or in combination with nivolumab. The trial targets patients with selected advanced solid tumors, including mesothelioma, ovarian, pancreatic, gastric, and non–small cell lung cancers.",True,0.98,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.descriptionModule.detailedDescription,EV,EV,,"CA008-002 is an open-label, international, multicohort phase I/IIa trial investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of BMS-986148 alone or in combination with the anti-PD-1 checkpoint inhibitor nivolumab. The study includes dose-escalation, dose-exploration, and dose-expansion phases involving patients with advanced (metastatic, recurrent, refractory, and/or unresectable) solid tumors of selected histologies: pleural or peritoneal mesothelioma, ovarian cancer, pancreatic cancer, gastric cancer, or non–small cell lung cancer (NSCLC).

In the dose-escalation phase, patients received BMS-986148 monotherapy intravenously either every 3 weeks (Part 1A) or once weekly for 3 weeks followed by 1 week off (Part 1B), or BMS-986148 combined with nivolumab every 3 weeks (Part 3A). Doses were escalated to determine the maximum tolerated dose (MTD) and recommended phase II dose. The primary endpoints are safety, tolerability, and dose-limiting toxicities (DLTs). 

During the dose-expansion phase (Parts 2 and 3B), patients with specific tumor types and confirmed high mesothelin expression (H-score ≥ 100) were treated at the recommended dose levels. Secondary objectives include the assessment of pharmacokinetics, immunogenicity, and preliminary clinical activity evaluated via RECIST v1.1 (or modified RECIST for mesothelioma).",,,,DetailedDescription,protocolSection.descriptionModule.detailedDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.conditions,TP,FP,['Advanced Cancer'],"['Advanced Solid Tumors', 'Mesothelioma', 'Pleural Mesothelioma', 'Peritoneal Mesothelioma', 'Ovarian Cancer', 'Pancreatic Cancer', 'Gastric Cancer', 'Non–Small Cell Lung Cancer']",False,0.0,disjoint,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.conditionsModule.keywords,EV,EV,,"['BMS-986148', 'Nivolumab', 'Mesothelin', 'Antibody-Drug Conjugate', 'ADC', 'Immunotherapy', 'Phase I/IIa', 'Checkpoint Inhibitor']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.studyType,TP,TP,INTERVENTIONAL,INTERVENTIONAL,True,1.0,exact,StudyType,protocolSection.designModule.studyType,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.patientRegistry,EV,EV,,False,,,,PatientRegistry,protocolSection.designModule.patientRegistry,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.phases,TP,TP,"['PHASE1', 'PHASE2']","['PHASE1', 'PHASE2']",True,1.0,exact,Phase,protocolSection.designModule.phases,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.allocation,TP,TP,NON_RANDOMIZED,NON_RANDOMIZED,True,1.0,exact,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModel,TP,TP,PARALLEL,PARALLEL,True,1.0,exact,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.designInfo.interventionModelDescription,EV,EV,,"This multicohort study comprises dose-escalation, dose-exploration, and dose-expansion phases that evaluate BMS-986148 alone or in combination with nivolumab.",,,,DesignInterventionModelDescription,protocolSection.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.designModule.designInfo.maskingInfo.masking,TP,TP,NONE,NONE,True,1.0,exact,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.designModule.enrollmentInfo.count,TP,TP,126,126,True,1.0,exact,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[0].description,EV,EV,,A mesothelin-directed antibody–drug conjugate (ADC) containing a fully human IgG1 anti-mesothelin mAb conjugated to tubulysin.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.armsInterventionsModule.interventions[1].description,EV,EV,,An anti-programmed death-1 (PD-1) mAb checkpoint inhibitor.,,,,InterventionDescription,protocolSection.armsInterventionsModule.interventions.description,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.eligibilityCriteria,TP,TP,"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* Must have pancreatic, ovarian, gastric, non-small cell cancer or mesothelioma. For dose expansion, must have tumor that is positive for mesothelin
* Expected to have life expectancy of at least 3 months
* Men and women 18 years old or older (or local age of majority)
* Must have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma
* ECOG of 0 to 1

Exclusion Criteria:

* Cancer metastases in the brain
* Moderate eye disorders
* Active infection or past hepatitis B or C infection
* Major surgery less than 1 month before the start of the study
* Uncontrolled heart disease
* Impaired liver or bone marrow function
* History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds","Inclusion Criteria:

*   Patients ≥ 18 years old.
*   Histologically confirmed selected advanced solid tumors: pleural or peritoneal mesothelioma (except sarcomatoid mesothelioma), ovarian cancer (except mucinous carcinoma), pancreatic cancer, gastric cancer, or NSCLC (adenocarcinoma only).
*   ≥ 1 lesion of measurable disease per RECIST v1.1 (or modified RECIST for malignant pleural mesothelioma).
*   Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
*   Patients must have progressed on or been intolerant of ≥ 1 standard treatment regimen; prior anticancer treatments (e.g., chemotherapy, radiotherapy, hormonal therapy, immunotherapy) were permitted.
*   Patients with NSCLC must have received prior immunotherapy, if available.
*   In the dose-expansion phase, patients were required to have an H-score of ≥ 100 for tumor-cell mesothelin expression.

Exclusion Criteria:

*   Active metastases in the central nervous system or, if the central nervous system was the only site of disease, prior exposure to BMS-986148 or other mesothelin-directed mAbs or ADCs.
*   Prior malignancy (except nonmelanoma skin cancers and in situ cancers).
*   History of uncontrolled or significant cardiovascular disease.
*   Chronic hepatitis.",True,0.87,success,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.healthyVolunteers,TP,TP,False,False,True,1.0,exact,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.sex,TP,TP,ALL,ALL,True,1.0,exact,Sex,protocolSection.eligibilityModule.sex,False,True,True,False,True,False
Gemini-3-Pro,protocolSection.eligibilityModule.minimumAge,TP,TP,18 Years,18 Years,True,1.0,exact,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.maximumAge,EV,EV,,N/A,,,,MaximumAge,protocolSection.eligibilityModule.maximumAge,True,False,True,False,False,False
Gemini-3-Pro,protocolSection.eligibilityModule.stdAges,TP,TP,"['ADULT', 'OLDER_ADULT']","['ADULT', 'OLDER_ADULT']",True,1.0,exact,StdAge,protocolSection.eligibilityModule.stdAges,False,True,True,False,True,False
